{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260528610886/en/IMFINZI%C2%AE-durvalumab-approved-in-the-US-in-first-and-only-immunotherapy-combination-for-patients-with-BCG-na%C3%AFve-high-risk-non-muscle-invasive-bladder-cancer", "message": "News view counter 766206 successfully enlarged"}